Cue Biopharma (NasdaqCM:CUE) has seen its one-year price target increase to $122.40 per share, a staggering rise of 2,900% from the previous estimate of $4.08 on April 12, 2026. This new target averages the analysts’ estimates, ranging from a low of $121.20 to a high of $126.00, and signifies an increase of 583.04% from the last reported closing price of $17.92.
A total of 50 funds hold positions in Cue Biopharma, reflecting a decrease of 12.28% (7 funds) in the last quarter. Institutional ownership increased by 20.66% to 21,790K shares. The average portfolio weight dedicated to CUE expanded by 329.12% to 0.08%. The current put/call ratio is 0.08, indicating a bullish sentiment.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
